Staphylococcus lugdunensis, a serious pathogen in periprosthetic joint infections: comparison to Staphylococcus aureus and Staphylococcus epidermidis.
OBJECTIVE
The aim of this study was to assess the characteristics of periprosthetic joint infection (PJI) due to Staphylococcus lugdunensis and to compare these to the characteristics of PJI due to Staphylococcus aureus and Staphylococcus epidermidis.


METHODS
A retrospective multicentre study including all consecutive cases of S. lugdunensis PJI (2000-2014) was performed. Eighty-eight cases of staphylococcal PJI were recorded: 28 due to S. lugdunensis, 30 to S. aureus, and 30 to S. epidermidis, as identified by Vitek 2 or API Staph (bioMérieux).


RESULTS
Clinical symptoms were more often reported in the S. lugdunensis group, and the median delay between surgery and infection was shorter for the S. lugdunensis group than for the S. aureus and S. epidermidis groups. Regarding antibiotic susceptibility, the S. lugdunensis strains were susceptible to antibiotics and 61% of the patients could be treated with levofloxacin + rifampicin. The outcome of the PJI was favourable for 89% of patients with S. lugdunensis, 83% with S. aureus, and 97% with S. epidermidis.


CONCLUSIONS
S. lugdunensis is an emerging pathogen with a pathogenicity quite similar to that of S. aureus. This coagulase-negative Staphylococcus must be identified precisely in PJI, in order to select the appropriate surgical treatment and antibiotics .
Microbiological Laboratory, Hôpital J. Ducuing, 15 rue Varsovie, 31300 Toulouse, France. Electronic address: julielourtet@hotmail.com.
J
J
Lourtet-Hascoët
Infectious Diseases Mobile Unit, J. Ducuing Hospital, Toulouse, France.
A
A
Bicart-See
Microbiological Laboratory, Hôpital J. Ducuing, 15 rue Varsovie, 31300 Toulouse, France.
M P
MP
Félicé
Traumatology and Orthopaedic Surgery Department, J. Ducuing Hospital, Toulouse, France.
G
G
Giordano
Infectious Diseases Mobile Unit, J. Ducuing Hospital, Toulouse, France.
E
E
Bonnet
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D007595:Joint Prosthesis / Q000382:microbiology*; D064704:Levofloxacin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016459:Prosthesis-Related Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery; D012189:Retrospective Studies; D012293:Rifampin / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery; D013211:Staphylococcus aureus / Q000187:drug effects / Q000472:pathogenicity*; D013212:Staphylococcus epidermidis / Q000187:drug effects / Q000472:pathogenicity*; D057787:Staphylococcus lugdunensis / Q000187:drug effects / Q000472:pathogenicity*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D012293:Rifampin
Periprosthetic joint infection; Staphylococcus aureus; Staphylococcus lugdunensis